TITLE:
Pemetrexed Plus Gemcitabine as Front-Line Chemotherapy for Patients With Malignant Pleural or Peritoneal Mesothelioma

CONDITION:
Mesothelioma

INTERVENTION:
Pemetrexed

SUMMARY:

      The purposes of this study are to determine:

        1. The safety of Pemetrexed plus Gemcitabine and any side effects that might be associated
           with the combination of these two drugs.

        2. Whether Pemetrexed plus Gemcitabine can help patients with mesothelioma live longer.

        3. Whether Pemetrexed plus Gemcitabine can make the tumor smaller or disappear, and for
           how long.

        4. To see if patients feel better while taking Pemetrexed plus Gemcitabine.
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 18 Years to N/A
Criteria:

        Inclusion Criteria:

          -  Diagnosis of mesothelioma that can be treated with chemotherapy

          -  Have received no prior chemotherapy for mesothelioma

          -  Have at least one measurable lesion

          -  Have an adequate performance status

          -  Sign an informed consent

        Exclusion Criteria:

          -  Previous treatment with chemotherapy for mesothelioma

          -  Treatment with an investigational drug within the last 30 days, previously completed
             or withdrawn from this study or any other study investigating Pemetrexed

          -  Treatment with radiation therapy within the last 4 weeks

          -  Brain metastasis that is uncontrolled

          -  Active infection or other serious condition
      
